TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06365840: PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR

Sponsor: ImmuneOncia Therapeutics Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,041,800

Rescue Site Savings

+$7,299,600

Unlock Full NCT06365840 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06365840 Rescue Dossier →